TR200202110T2 - "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri" - Google Patents

"5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"

Info

Publication number
TR200202110T2
TR200202110T2 TR2002/02110T TR200202110T TR200202110T2 TR 200202110 T2 TR200202110 T2 TR 200202110T2 TR 2002/02110 T TR2002/02110 T TR 2002/02110T TR 200202110 T TR200202110 T TR 200202110T TR 200202110 T2 TR200202110 T2 TR 200202110T2
Authority
TR
Turkey
Prior art keywords
oxy
naphthyl
methyl
crystals
dion
Prior art date
Application number
TR2002/02110T
Other languages
English (en)
Inventor
Oe Takayuki
Ueno Hiroaki
Maruyama Akira
Masuda Katsuhiko
Original Assignee
Mitsubishi Chemical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corporation filed Critical Mitsubishi Chemical Corporation
Publication of TR200202110T2 publication Critical patent/TR200202110T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)

Abstract

Mevcut bulus, 5-[{6-(2-flüoro benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion'un kararli ve yeni D tipi kristallerine iliskin olup, bunlar asagidaki hastaliklarin tedavisine yönelik terapötik ilaçlarda aktif bilesen olarak kullanilmaya uygundur: diyabet ve komplikasyonlari, hiperlipidemi ve komplikasyonlari, hiperürisemi, lösemi ve pankreatit.
TR2002/02110T 1998-11-20 1999-11-19 "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri" TR200202110T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20

Publications (1)

Publication Number Publication Date
TR200202110T2 true TR200202110T2 (tr) 2002-10-21

Family

ID=18233859

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2002/02109T TR200202109T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri
TR2001/01901T TR200101901T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri
TR2002/02103T TR200202103T2 (tr) 1998-11-20 1999-11-19 ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri''
TR2002/02110T TR200202110T2 (tr) 1998-11-20 1999-11-19 "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"

Family Applications Before (3)

Application Number Title Priority Date Filing Date
TR2002/02109T TR200202109T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri
TR2001/01901T TR200101901T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri
TR2002/02103T TR200202103T2 (tr) 1998-11-20 1999-11-19 ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri''

Country Status (23)

Country Link
US (3) US6541493B1 (tr)
EP (1) EP1131310B1 (tr)
JP (1) JP3784001B2 (tr)
KR (1) KR100652326B1 (tr)
CN (1) CN1326449A (tr)
AT (1) ATE315552T1 (tr)
AU (1) AU1185100A (tr)
BR (1) BR9916795A (tr)
CA (1) CA2351727C (tr)
CZ (1) CZ20011763A3 (tr)
DE (1) DE69929476T2 (tr)
ES (1) ES2257104T3 (tr)
HU (1) HUP0104139A3 (tr)
ID (1) ID30064A (tr)
IL (1) IL143177A0 (tr)
NO (1) NO20012444L (tr)
NZ (1) NZ512429A (tr)
PL (1) PL348502A1 (tr)
PT (1) PT1131310E (tr)
TR (4) TR200202109T2 (tr)
TW (2) TWI272944B (tr)
WO (1) WO2000031055A1 (tr)
ZA (1) ZA200104081B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体
MXPA02005008A (es) * 1999-11-19 2003-10-14 Johnson & Johnson Formas de estado solido de 5-((6 -((2-fluorofenil) metoxi)-2 -naftalenil)metil)-2, 4-tiazolidinediona.
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
ES2423991T3 (es) 2008-02-04 2013-09-26 Pfizer Limited Forma polimórfica de un derivado de [1,2,4]triazolo[4,3-a]piridina para el tratamiento de enfermedades inflamatorias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体

Also Published As

Publication number Publication date
PL348502A1 (en) 2002-05-20
TWI272944B (en) 2007-02-11
KR100652326B1 (ko) 2006-11-29
EP1131310A1 (en) 2001-09-12
HUP0104139A2 (hu) 2002-03-28
JP3784001B2 (ja) 2006-06-07
TR200202109T2 (tr) 2002-11-21
CA2351727C (en) 2008-09-23
EP1131310B1 (en) 2006-01-11
WO2000031055A1 (en) 2000-06-02
ZA200104081B (en) 2002-05-20
NZ512429A (en) 2003-11-28
ES2257104T3 (es) 2006-07-16
HUP0104139A3 (en) 2003-12-29
NO20012444D0 (no) 2001-05-18
US20060149075A1 (en) 2006-07-06
TWI250156B (en) 2006-03-01
BR9916795A (pt) 2002-04-09
JP2002530392A (ja) 2002-09-17
DE69929476T2 (de) 2006-09-14
NO20012444L (no) 2001-07-18
TW200613291A (en) 2006-05-01
US20030158241A1 (en) 2003-08-21
TR200202103T2 (tr) 2002-11-21
CN1326449A (zh) 2001-12-12
KR20010101033A (ko) 2001-11-14
CA2351727A1 (en) 2000-06-02
CZ20011763A3 (cs) 2001-10-17
ID30064A (id) 2001-11-01
IL143177A0 (en) 2002-04-21
DE69929476D1 (de) 2006-04-06
TR200101901T2 (tr) 2002-04-22
AU1185100A (en) 2000-06-13
PT1131310E (pt) 2006-05-31
ATE315552T1 (de) 2006-02-15
US6541493B1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
WO1999010494A3 (en) Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
SE8804629D0 (sv) New therapeutically active compounds
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
TR200201636T2 (tr) Sübstitüe edilmiş oksazolidinonlar ve bunların kullanımı
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
GEP20032958B (en) Adenosine Derivatives
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
WO2003028715A3 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
NZ507203A (en) Use of dexmedetomidine for ICU sedation
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
TW200833321A (en) Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases
TR200202110T2 (tr) "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"
CO4940452A1 (es) Modificacion a cristal de una sustancia activa de medicamen- to
EP1266663A4 (en) EOSINOPHILE SPECIFIC APOPTOSE INDUCTORS
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DK0918469T3 (da) Fremgangsmåder og præparater til at øge den vævsanaerobe arbejdskapacitet
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection